对比分析瑞舒伐他汀与辛伐他汀对心肌梗死患者血清C反应蛋白及基质金属蛋白酶―9水平影响.docVIP

对比分析瑞舒伐他汀与辛伐他汀对心肌梗死患者血清C反应蛋白及基质金属蛋白酶―9水平影响 　　【摘要】 目的 研究心肌梗死患者应用瑞舒伐他汀和辛伐他汀对血清C反应蛋白（CRP）、基质金属蛋白酶-9（MMP-9）水平的影响。方法 86例心肌梗死患者， 随机分为甲组和乙组， 各43例。甲组患者采用瑞舒伐他汀治疗， 乙组患者采用辛伐他汀治疗。比较两组患者治疗前后血清CRP、MMP-9水平。结果 治疗前， 两组患者CRP、MMP-9水平比较差异无统计学意义（P0.05）；治疗后， 甲组患者血清CRP为（2.05±0.32）mg/L、MMP-9为（110.5±12.8）ng/L， 均低于乙组的（3.12±0.47）mg/L、（143.7±15.3）ng/L， 　　差异具有统计学意义（P0.05）。结论 在心肌梗死的临床治疗中， 瑞舒伐他汀能起到更好的清除炎症因子、降低MMP-9水平的效果， 有助于促进患者的康复， 值得推广应用。 　　【关键词】 瑞舒伐他汀；辛伐他汀；心肌梗死；C反应蛋白；基质金属蛋白酶-9 　　DOI：10.14163/j.cnki.11-5547/r.2017.05.056 　　Comparative analysis of influence by rosuvastatin and simvastatin on serum C-reactive protein and matrix metalloproteinase-9 levels in myocardial infarction patients ZHONG Shu-ping. Guangzhou City Zengcheng District Zhengguo Health Center， Guangzhou 511390， China 　　【Abstract】 Objective To research influence by rosuvastatin and simvastatin on serum C-reactive protein （CRP） and matrix metalloproteinase-9 （MMP-9） levels in myocardial infarction patients. Methods A total of 86 patients with myocardial infarction were randomly divided into group A and group B， with 43 cases in each group. Group A received rosuvastatin for treatment， and group B received simvastatin for treatment. Comparison was made on serum CRP and MMP-9 levels before and after treatment between the two groups. Results Before treatment， there was no statistically significant difference of CRP and MMP-9 levels between the two groups （P0.05）. After treatment， group A had serum CRP as （2.05±0.32） mg/L and MMP-9 as （110.5±12.8） ng/L， which were all lower than （3.12±0.47） mg/L and （143.7±15.3） ng/L in group B， and their difference had statistical significance （P0.05）. Conclusion In clinical treatment of myocardial infarction， rosuvastatin provides better effect in eliminating inflammatory factor and reducing MMP-9 level. It is helpful to accelerate rehabilitation in patients， and it is worth promoting and applying. 　　【Key words】 Rosuvastatin； Simvastatin； Myocardial infarction； C-reactive protein； Matrix metal